A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J Levis, Donald Small

Research output: Contribution to journalArticle

Abstract

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. Lestaurtinib was administered orally for 8 weeks, initially at a dose of 60 mg twice daily, escalating to 80 mg twice daily, and was generally well tolerated. Clinical activity, manifest as transient reductions in bone marrow and peripheral-blood blasts or longer periods of transfusion independence, was seen in 3 (60%) of 5 patients with mutated FLT3 and 5 (23%) of 22 evaluable wild-type FLT3 patients. Laboratory data demonstrated that clinical responses occurred where the presence of sustained FLT3-inhibitory drug levels were combined with in vitro cytotoxic sensitivity of blasts to lestaurtinib. Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients.

Original languageEnglish (US)
Pages (from-to)3262-3270
Number of pages9
JournalBlood
Volume108
Issue number10
DOIs
StatePublished - Nov 15 2006
Externally publishedYes

Fingerprint

Chemotherapy
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Drug Therapy
Therapeutics
lestaurtinib
Mutation
Bone
Blood
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. / Knapper, Steven; Burnett, Alan K.; Littlewood, Tim; Kell, W. Jonathan; Agrawal, Sam; Chopra, Raj; Clark, Richard; Levis, Mark J; Small, Donald.

In: Blood, Vol. 108, No. 10, 15.11.2006, p. 3262-3270.

Research output: Contribution to journalArticle

Knapper, Steven ; Burnett, Alan K. ; Littlewood, Tim ; Kell, W. Jonathan ; Agrawal, Sam ; Chopra, Raj ; Clark, Richard ; Levis, Mark J ; Small, Donald. / A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. In: Blood. 2006 ; Vol. 108, No. 10. pp. 3262-3270.
@article{79ecdbb29f594c0b8ef8c943d5ae1d3d,
title = "A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy",
abstract = "Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. Lestaurtinib was administered orally for 8 weeks, initially at a dose of 60 mg twice daily, escalating to 80 mg twice daily, and was generally well tolerated. Clinical activity, manifest as transient reductions in bone marrow and peripheral-blood blasts or longer periods of transfusion independence, was seen in 3 (60{\%}) of 5 patients with mutated FLT3 and 5 (23{\%}) of 22 evaluable wild-type FLT3 patients. Laboratory data demonstrated that clinical responses occurred where the presence of sustained FLT3-inhibitory drug levels were combined with in vitro cytotoxic sensitivity of blasts to lestaurtinib. Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients.",
author = "Steven Knapper and Burnett, {Alan K.} and Tim Littlewood and Kell, {W. Jonathan} and Sam Agrawal and Raj Chopra and Richard Clark and Levis, {Mark J} and Donald Small",
year = "2006",
month = "11",
day = "15",
doi = "10.1182/blood-2006-04-015560",
language = "English (US)",
volume = "108",
pages = "3262--3270",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

AU - Knapper, Steven

AU - Burnett, Alan K.

AU - Littlewood, Tim

AU - Kell, W. Jonathan

AU - Agrawal, Sam

AU - Chopra, Raj

AU - Clark, Richard

AU - Levis, Mark J

AU - Small, Donald

PY - 2006/11/15

Y1 - 2006/11/15

N2 - Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. Lestaurtinib was administered orally for 8 weeks, initially at a dose of 60 mg twice daily, escalating to 80 mg twice daily, and was generally well tolerated. Clinical activity, manifest as transient reductions in bone marrow and peripheral-blood blasts or longer periods of transfusion independence, was seen in 3 (60%) of 5 patients with mutated FLT3 and 5 (23%) of 22 evaluable wild-type FLT3 patients. Laboratory data demonstrated that clinical responses occurred where the presence of sustained FLT3-inhibitory drug levels were combined with in vitro cytotoxic sensitivity of blasts to lestaurtinib. Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients.

AB - Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. Lestaurtinib was administered orally for 8 weeks, initially at a dose of 60 mg twice daily, escalating to 80 mg twice daily, and was generally well tolerated. Clinical activity, manifest as transient reductions in bone marrow and peripheral-blood blasts or longer periods of transfusion independence, was seen in 3 (60%) of 5 patients with mutated FLT3 and 5 (23%) of 22 evaluable wild-type FLT3 patients. Laboratory data demonstrated that clinical responses occurred where the presence of sustained FLT3-inhibitory drug levels were combined with in vitro cytotoxic sensitivity of blasts to lestaurtinib. Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients.

UR - http://www.scopus.com/inward/record.url?scp=33751173636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751173636&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-04-015560

DO - 10.1182/blood-2006-04-015560

M3 - Article

VL - 108

SP - 3262

EP - 3270

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -